These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38348362)

  • 1. An integrated precision medicine approach in major depressive disorder: a study protocol to create a new algorithm for the prediction of treatment response.
    Baune BT; Minelli A; Carpiniello B; Contu M; Domínguez Barragán J; Donlo C; Ferensztajn-Rochowiak E; Glaser R; Kelch B; Kobelska P; Kolasa G; Kopeć D; Martínez de Lagrán Cabredo M; Martini P; Mayer MA; Menesello V; Paribello P; Perera Bel J; Perusi G; Pinna F; Pinna M; Pisanu C; Sierra C; Stonner I; Wahner VTH; Xicota L; Zang JCS; Gennarelli M; Manchia M; Squassina A; Potier MC; Rybakowski F; Sanz F; Dierssen M
    Front Psychiatry; 2023; 14():1279688. PubMed ID: 38348362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
    Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
    World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study.
    Lundberg J; Cars T; Lööv SÅ; Söderling J; Sundström J; Tiihonen J; Leval A; Gannedahl A; Björkholm C; Själin M; Hellner C
    JAMA Psychiatry; 2023 Feb; 80(2):167-175. PubMed ID: 36515938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current treatments used in clinical practice for major depressive disorder and treatment resistant depression in England: A retrospective database study.
    Denee T; Kerr C; Ming T; Wood R; Tritton T; Middleton-Dalby C; Massey O; Desai M
    J Psychiatr Res; 2021 Jul; 139():172-178. PubMed ID: 34077893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of treatment resistant depression among major depressive disorder patients in Israel.
    Sharman Moser S; Chodick G; Gelerstein S; Barit Ben David N; Shalev V; Stein-Reisner O
    BMC Psychiatry; 2022 Aug; 22(1):541. PubMed ID: 35948895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. rTMS combined with CBT as a next step in antidepressant non-responders: a study protocol for a randomized comparison with current antidepressant treatment approaches.
    Dalhuisen I; Smit F; Spijker J; van Oostrom I; van Exel E; van Mierlo H; de Waardt D; Arns M; Tendolkar I; van Eijndhoven P
    BMC Psychiatry; 2022 Feb; 22(1):88. PubMed ID: 35123427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression.
    Olgiati P; Serretti A; Souery D; Dold M; Kasper S; Montgomery S; Zohar J; Mendlewicz J
    J Affect Disord; 2018 Feb; 227():777-786. PubMed ID: 29254066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder.
    Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
    Curr Med Res Opin; 2021 Jan; 37(1):123-133. PubMed ID: 33124940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA trial).
    Minelli A; Barlati S; Vitali E; Bignotti S; Dattilo V; Tura GB; Maffioletti E; Giacopuzzi E; Santoro V; Perusi G; Cobelli C; Magri C; Bonizzato S; Bocchio-Chiavetto L; Spina E; Vita A; Gennarelli M
    Trials; 2021 Dec; 22(1):896. PubMed ID: 34895291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personal recovery associated with deep brain stimulation for treatment-resistant depression: A constructivist grounded theory study.
    Raffin Bouchal DS; Ferguson AL; Green T; McAusland L; Kiss Z; Ramasubbu R
    J Psychiatr Ment Health Nurs; 2023 Oct; 30(5):1005-1018. PubMed ID: 37002931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding treatment-resistant depression using "omics" techniques: A systematic review.
    Amasi-Hartoonian N; Pariante CM; Cattaneo A; Sforzini L
    J Affect Disord; 2022 Dec; 318():423-455. PubMed ID: 36103934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Correlates of Treatment-Resistant Depression: Insights from Polygenic Scores Across Cognitive, Temperamental, and Sleep Traits in the All of US cohort.
    Xu B; Forthman KL; Kuplicki R; Ahern J; Loughnan R; Naber F; Thompson WK; Nemeroff CB; Paulus MP; Fan CC
    medRxiv; 2024 Jul; ():. PubMed ID: 39006419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An episode level evaluation of the treatment journey of patients with major depressive disorder and treatment-resistant depression.
    Wu B; Cai Q; Sheehan JJ; Benson C; Connolly N; Alphs L
    PLoS One; 2019; 14(8):e0220763. PubMed ID: 31393922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence and economic burden of treatment-resistant depression in Thailand.
    Prasartpornsirichoke J; Pityaratstian N; Poolvoralaks C; Sirinimnualkul N; Ormtavesub T; Hiranwattana N; Phonsit S; Rungnirundorn T
    BMC Public Health; 2023 Aug; 23(1):1541. PubMed ID: 37573321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis.
    Pilon D; Joshi K; Sheehan JJ; Zichlin ML; Zuckerman P; Lefebvre P; Greenberg PE
    PLoS One; 2019; 14(10):e0223255. PubMed ID: 31600244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life burden associated with treatment-resistant depression in UK patients: Quantitative results from a mixed-methods non-interventional study.
    Rathod S; Denee T; Eva J; Kerr C; Jacobsen N; Desai M; Baldock L; Young AH
    J Affect Disord; 2022 Mar; 300():551-562. PubMed ID: 34965398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic impact of treatment-resistant depression: A retrospective observational study.
    Pérez-Sola V; Roca M; Alonso J; Gabilondo A; Hernando T; Sicras-Mainar A; Sicras-Navarro A; Herrera B; Vieta E
    J Affect Disord; 2021 Dec; 295():578-586. PubMed ID: 34509073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts.
    Fabbri C; Hagenaars SP; John C; Williams AT; Shrine N; Moles L; Hanscombe KB; Serretti A; Shepherd DJ; Free RC; Wain LV; Tobin MD; Lewis CM
    Mol Psychiatry; 2021 Jul; 26(7):3363-3373. PubMed ID: 33753889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.